Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$200.00 | -$0.08 | Beat |
| May 14, 2026 | -$200.00 | -$0.07 | Beat |
| Mar 12, 2026 | – | -$0.06 | |
| Nov 12, 2025 | – | -$0.04 | |
| Aug 15, 2025 | – | -$0.09 | |
| May 19, 2025 | – | -$2.15 |